. Jennifer Schranz, Senior Vice President, Head of Rare Diseases The human cost of a system out of balance Over
Category: Science
Testing the hypothesis: a focused pilot for AI in healthcare
Every scientific breakthrough begins with a question: can this medicine extend life, restore balance, or meaningfully change what is possible
Always one step ahead: Anne Petit on making medicines happen
Anne Petit does not wait for instructions. She knows that in pharmaceutical development, her team often moves first. “We always
From data to decisions: how Ipsen turns medical data into action for patients
Balancing benefit and risk: Nisha Vora on the science of pharmacovigilance
“My job is to be a guardian of patient safety.” As Safety Science Director, she works across both early development
Engaging the immune system in AML: A new frontier in the pursuit of durable outcomes
By Ivan Diaz-Padilla, Senior Vice President and Global Head, Oncology Therapeutic Area Unit, R&D Acute myeloid leukaemia (AML) remains a
Choosing the hardest problems: why Ipsen focuses where unmet need is greatest
By Christelle Huguet, EVP & Head of R&D, Ipsen In biopharmaceutical research, not all challenges are equal. Some of the most
Why post approval evidence is redefining the future of patient care
By Sandra Silvestri, for Ipsen.com In today’s rapidly evolving treatment landscape the approval of a medicine is no longer the
A moment worth remembering: what SCALE tells us about the future of aesthetics
Olivia Brown, EVP, Head of Neuroscience There are moments that stay with you. Not because of a single slide or
Right medicine, right person: Jacintha Sivarajah on science with purpose
“All medicines have side effects, but it’s just about trying to minimize the impact through providing the information patients and clinicians need or finding other